Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Common Equity (2016 - 2025)

Adma Biologics (ADMA) has disclosed Common Equity for 13 consecutive years, with $477.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 36.76% year-over-year to $477.3 million, compared with a TTM value of $477.3 million through Dec 2025, up 36.76%, and an annual FY2025 reading of $477.3 million, up 36.76% over the prior year.
  • Common Equity was $477.3 million for Q4 2025 at Adma Biologics, up from $431.2 million in the prior quarter.
  • Across five years, Common Equity topped out at $477.3 million in Q4 2025 and bottomed at $100.4 million in Q3 2022.
  • Average Common Equity over 5 years is $207.2 million, with a median of $149.1 million recorded in 2023.
  • The sharpest move saw Common Equity fell 11.03% in 2023, then skyrocketed 158.14% in 2024.
  • Year by year, Common Equity stood at $141.2 million in 2021, then increased by 7.65% to $152.0 million in 2022, then fell by 11.03% to $135.2 million in 2023, then surged by 158.14% to $349.0 million in 2024, then soared by 36.76% to $477.3 million in 2025.
  • Business Quant data shows Common Equity for ADMA at $477.3 million in Q4 2025, $431.2 million in Q3 2025, and $398.3 million in Q2 2025.